Advertisement

Polymorphisms of BIRC5 Gene is Associated with Chronic HBV Infection in Iranian Population

  • Bita Moudi
  • Zahra HeidariEmail author
  • Hamidreza Mahmoudzadeh-Sagheb
Original Research Article
  • 6 Downloads

Abstract

Survivin can affect the progression of infection and is considered as a marker of various malignancies. The aim of the study was to investigate the possible association of gene polymorphisms of survivin (-1547A/G, -644C/T, -625 C/G, -241C/T, -31G/C, -141G/C) and chronic hepatitis B infection in Iranian patients. The genotypes of survivin SNPs were investigated by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method using 100 chronic HBV infected patients (HBV), 40 spontaneously recovered HBV subjects and 100 healthy controls (C). Serum level of survivin was determined using ELISA method. The -1547G, -625C, -241T and -31C alleles were associated with increased susceptibility to chronic hepatitis B infection (P = 0.001, P < 0.001, P = 0.003 and P < 0.001 respectively). Chronic HBV patients with -625CC, -241TT and -31CC genotypes had higher levels of survvin. Survivin -1547A/G, -625 C/G, -241C/T and -31G/C gene polymorphisms may be associated with chronic HBV susceptibility in Iranian HBV patients.

Keywords

Chronic hepatitis B Polymorphisms Survivin 

Abbreviations

SNP

Single nucleotide polymorphisms

HBV

Hepatitis B virus

SR

Spontaneously recovered

PCR-RFLP

Polymerase chain reaction restriction fragment length polymorphism

ELISA

Enzyme-linked immunosorbent assay

IAPs

Inhibitor of apoptosis family of proteins

BIRC5

Baculoviral inhibitor of apoptosis repeat containing 5

RT-PCR

Reverse transcription polymerase chain reaction

Notes

Acknowledgements

The authors would like to thank all participants who willingly participated in this study. We appreciate all who helped us in this work, especially in the Blood Transfusion Research Center of Zahedan, Iran. This study was approved by the Institutional Ethics Committee of the Zahedan University of Medical Sciences (IR.ZAUMS.REC.1395.159, Grant Number 7868).

Author’s Contribution

BM, ZH, HM-S conceived and co-designed the study, supervised all the experimental design, analyzed the results, and drafted the manuscript. All authors read, modified and approved the final version of the manuscript. These authors equally contributed to this work.

Funding

This project was supported by the vice chancellor of Research and Technology of Zahedan University of Medical Sciences (ZUMS) and Infectious Diseases and Tropical Medicine Research Center, Zahedan University of Medical Sciences.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was written and signed by all individual participants included in the study.

References

  1. 1.
    Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–500.CrossRefGoogle Scholar
  2. 2.
    Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H. Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection. Infect Genet Evol. 2016;44:94–105.CrossRefGoogle Scholar
  3. 3.
    Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Hashemi M. Association between IL-10 gene promoter polymorphisms (-592 A/C, -819 T/C, -1082 A/G) and susceptibility to HBV infection in an Iranian population. Hepat Mon. 2016.  https://doi.org/10.5812/hepatmon.32427.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Hashemi M. Gene polymorphisms of macrophage migration inhibitory factor affect susceptibility to chronic hepatitis B virus infection in an Iranian cohort. Microbiol Immunol. 2016;60(6):390–6.CrossRefGoogle Scholar
  5. 5.
    Heidari Z, Moudi B, Mahmoudzadeh-Sagheb H, Hashemi M. The correlation between interferon lambda 3 gene polymorphisms and susceptibility to hepatitis B virus infection. Hepat Mon. 2016;16(3):e34266.CrossRefGoogle Scholar
  6. 6.
    Heidari Z, Moudi B, Mahmoudzade Sagheb H, Moudi M. Association of TNF-a gene polymorphisms with production of protein and the susceptibility to chronic hepatitis B infection in Iranian population. Hepat Mon. 2016.  https://doi.org/10.5812/hepatmon.41984.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sharief MK, Noori MA, Douglas MR, Semra YK. Upregulated survivin expression in activated T lymphocytes correlates with disease activity in multiple sclerosis. Eur J Neurol. 2002;9(5):503–10.CrossRefGoogle Scholar
  8. 8.
    Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc. 2001;34(4):207–12.CrossRefGoogle Scholar
  9. 9.
    Liu YZ, Hou FQ, Ding P, Ren YY, Li SH, Wang GQ. Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients. Virol J. 2012;9:274.CrossRefGoogle Scholar
  10. 10.
    Hsieh YS, Tsai CM, Yeh CB, Yang SF, Hsieh YH, Weng CJ. Survivin T9809C, an SNP located in 3′-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann Surg Oncol. 2012;19(3):011–2123.Google Scholar
  11. 11.
    Li Y, Wang J, Jiang F, Lin W, Meng W. Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study. BMC Med Genet. 2012;13(1):1471–2350.Google Scholar
  12. 12.
    Heidari Z, Mahmoudzadeh-Sagheb HR, Hashemi M, Rigi-Ladiz MA. Quantitative analysis of interdental gingiva in patients with chronic periodontitis and transforming growth factor-β1 29C/T gene polymorphisms. J Periodontol. 2014;85(2):281–9.CrossRefGoogle Scholar
  13. 13.
    Lee JS, Kim JH, Park BL, Cheong HS, Kim JY, Park TJ, et al. Lack of association of BIRC5 polymorphisms with clearance of HBV infection and HCC occurrence in a Korean population. Genomics Inform. 2009;7(4):195–202.CrossRefGoogle Scholar
  14. 14.
    Montorsi M, Maggioni M, Falleni M, Pellegrini C, Donadon M, Torzilli G, et al. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. Hepatogastroenterology. 2007;54(79):2040–4.PubMedGoogle Scholar
  15. 15.
    Guo G, Zhang Q, Yu Z, Li J, Ding Z, Tan W. Correlation between survivin genetic polymorphisms and lung cancer susceptibility. Int J Clin Exp Pathol. 2015;8(6):7426–30.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2008;60(1):31–9.CrossRefGoogle Scholar
  17. 17.
    Boidot R, Vegran F, Jacob D, Chevrier S, Gangneux N, Taboureau J, et al. The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosomes Cancer. 2008;47(4):299–308.CrossRefGoogle Scholar
  18. 18.
    Han CH, Wei Q, Lu KK, Liu Z, Mills GB, Wang LE. Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med. 2009;2(4):289–99.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Li XB, Li SN, Yang ZH, Cao L, Duan FL, Sun XW. Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. DNA Cell Biol. 2013;32(5):236–42.CrossRefGoogle Scholar
  20. 20.
    Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, et al. Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer. 2012;22(1):35–7.CrossRefGoogle Scholar
  21. 21.
    Yamak N, Yaykasli KO, Yilmaz U, Eroz R, Uzunlar AK, Ankarali H, et al. Association between survivin gene polymorphisms and the susceptibility to colon cancer development in the Turkish population. Asian Pac J Cancer Prev. 2014;15(20):8963–7.CrossRefGoogle Scholar
  22. 22.
    Kostic M, Nikolic N, Ilic B, Carkic J, Milenkovic S, Vukadinovic M. Analysis of polymorphism in the survivin gene promoter as a potential risk factor for head and neck cancers development. Srp Arh Celok Lek. 2013;141(5–6):304–7.CrossRefGoogle Scholar
  23. 23.
    Li Y, Wang J, Jiang F, Lin W, Meng W. Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study. BMC Med Genet. 2012;13:1.  https://doi.org/10.1186/1471-2350-13-1.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Bayram S, Akkiz H, Bekar A, Akgollu E. The association between the survivin -31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol. 2011;35(6):555–9.  https://doi.org/10.1016/j.canep.2011.01.004.CrossRefPubMedGoogle Scholar
  25. 25.
    Yang E, Ma S, Peng H, Sun D. Correlation between BIRC5 -625G/C polymorphism and hepatocellular carcinoma. Int J Clin Exp Pathol. 2016;9(2):2330–4.Google Scholar
  26. 26.
    Srivastava K, Srivastava A, Mittal B. Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep. 2012;39(2):1509–16.CrossRefGoogle Scholar
  27. 27.
    Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23(9):527–37.CrossRefGoogle Scholar
  28. 28.
    Lamp M, Saare M, Kadastik U, Karro H, Salumets A, Uibo R, et al. Survivin promoter polymorphisms and autoantibodies in endometriosis. J Reprod Immunol. 2012;96(1–2):95–100.CrossRefGoogle Scholar
  29. 29.
    Yang X, Xiong G, Chen X, Xu X, Wang K, Fu Y, et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135(10):1341–9.CrossRefGoogle Scholar
  30. 30.
    Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003;22(11):2729–40.CrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2019

Authors and Affiliations

  • Bita Moudi
    • 1
    • 2
  • Zahra Heidari
    • 1
    • 2
    Email author
  • Hamidreza Mahmoudzadeh-Sagheb
    • 1
    • 2
  1. 1.Infectious Diseases and Tropical Medicine Research CenterZahedan University of Medical SciencesZahedanIran
  2. 2.Department of Histology, School of MedicineZahedan University of Medical SciencesZahedanIran

Personalised recommendations